Cliff Asness's TRAX Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 28,812 shares of First Tracks Biotherapeutics, Inc. (TRAX) worth $579,696, representing 0.00% of the portfolio. First purchased in 2026-Q2, this recently established position has been held for 1 quarters.
Based on recent 13F filings, Cliff Asness has initiated a new position in TRAX, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's First Tracks Biotherapeutics (TRAX) Holding Value Over Time
Track share changes against reported price movement
Quarterly First Tracks Biotherapeutics (TRAX) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +28,812 | New Buy | 28,812 | $20.12 |
Cliff Asness's First Tracks Biotherapeutics Investment FAQs
Cliff Asness first purchased First Tracks Biotherapeutics, Inc. (TRAX) in Q2 2026, acquiring 28,812 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held First Tracks Biotherapeutics, Inc. (TRAX) for 1 quarters since Q2 2026.
Cliff Asness's largest addition to First Tracks Biotherapeutics, Inc. (TRAX) was in Q2 2026, adding 28,812 shares worth $579,696.
According to the latest 13F filing for Q2 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 28,812 shares of First Tracks Biotherapeutics, Inc. (TRAX), valued at approximately $579,696.
As of the Q2 2026 filing, First Tracks Biotherapeutics, Inc. (TRAX) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in First Tracks Biotherapeutics, Inc. (TRAX) was 28,812 shares, as reported at the end of Q2 2026.